MARIGOLD: A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Sponsor: Amgen
Full Title
Protocol 20210033: A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda® (Pembrolizumab) in Subjects with Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Study Treatment
Pembrolizumab biosimilar candidate ABP 234 + platinum doublet chemotherapy vs pembrolizumab + platinum doublet chemotherapy
Eligibility/Info
Metastatic non-small cell lung cancer without prior systemic therapy in the advanced/metastatic setting.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
